POST 01173E : MALARIA VACCINE CANDIDATE

POST 01173E : MALARIA VACCINE CANDIDATE 17 October 2007 _______________________________________ Early findings from a malaria vaccine trial among African infants are promising, based on a research article published today Oct 17. In a double-blind trial of 214 infants in Mozambique, the malaria vaccine RTS,S/AS02D was found to be both safe and efficacious; vaccinated infants had a 65% reduction in risk of new infection. The article can only be downloaded on a pay/article basis or with a subscription. However you can read more details in the press release on the GAVI site. ______________________________________________________________________________ All members of the TechNet21 e-Forum are invited to send comments on any posting or to use the forum to raise a new discussion or request technical information in relation to immunization services. The comments made in this forum are the sole responsibility of the writers and do not in any way mean that they are endorsed by any of the organizations and agencies to which the authors may belong. ______________________________________________________________________________ Visit the TECHNET21 Website at http://www.technet21.org You will find instructions to subscribe, a direct access to archives, links to reference documents and other features. ______________________________________________________________________________ To UNSUBSCRIBE, send a message to : [[email protected]][email protected][/email] Leave the subject area BLANK In the message body, write unsubscribe TECHNET21E ______________________________________________________________________________ The World Health Organization and UNICEF support TechNet21. The TechNet21 e-Forum is a communication/information tool for generation of ideas on how to improve immunization services. It is moderated by Claude Letarte and is hosted in cooperation with the Centre de coopération internationale en santé et développement, Québec, Canada (www.ccisd.org ______________________________________________________________________________